Treatment | PBT2 | physical function | Transcriptome | Proteome | Metabolome | Target | Reference | blinded | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CID (PubChem) | 10016012 | ChEMBL | locomotion on solid media | |||||||||||||
Concentration | Exposure time | Food | Growth medium | Special additives | C. elegans strain | Temperature | Change compared to control | Percentual change compared to control | p < 0.05 | notes | ||||||
10 µg/ml | whole life; start: L4 | OP50 | NGM agar | Ampicillin | AM140 {rmIs132 [unc-54p::Q35::YFP]} | 25 °C | up | yes | A7-A10; Paralysis assay; no significant changes at A5 & A6 | Cherny, R. A., Ayton, S., Finkelstein, D. I., Bush, A. I., McColl, G., & Massa, S. M. (2012). PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington's disease. Journal of Huntington's disease, 1(2), 211-219. |